A systematic evaluation of research on the risk and outcomes of COVID-19 in patients with psoriasis and psoriatic arthritis treated with biological therapies has found high risk of bias in all of the studies, among other quality issues.

Therefore, investigators reporting in the Journal of Investigative Dermatology, published by Elsevier, conclude that neither a definite statement on risk nor management recommendations can be made based on currently published data.

Read the full article at scitechdaily.com